SCHEDULE: Invus Group Discloses 9.99% Stake in Eloxx Pharmaceuticals

Investment entities led by Raymond Debbane have reported a 9.99% beneficial ownership stake in Eloxx Pharmaceuticals, Inc. as of June 9, 2026.

Summary

• A group of investment entities, including Invus Public Equities, L.P. and Avicenna Life Sci Master Fund LP, filed a Schedule 13G reporting a collective beneficial ownership of 403,586 shares of Eloxx Pharmaceuticals, Inc.
• The reported stake represents 9.99% of the company's issued and outstanding common stock.
• The holdings consist of 400,000 shares and 3,586 shares issuable upon the exercise of pre-funded warrants.
• The reporting persons are subject to a 9.99% beneficial ownership limitation, which restricts the exercise of additional warrants if it would cause their ownership to exceed this threshold.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure indicating stable institutional interest without signaling immediate strategic shifts.

Positives

• Significant institutional interest from a group of entities managed by Raymond Debbane, signaling long-term investment confidence.
• The reporting persons have certified that the securities were not acquired for the purpose of changing or influencing the control of the issuer.

Negatives

• The 9.99% ownership cap limits the immediate ability of the reporting persons to increase their stake without further regulatory filings or changes to the beneficial ownership limitation.

Risks

• The investment is subject to a Beneficial Ownership Limitation, which may restrict the liquidity or conversion of held warrants.
• The reporting persons' ability to influence the company is limited by their passive investment certification.

Future Outlook

The filing does not provide a forward-looking business outlook, as it is a regulatory disclosure of beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing reflects typical institutional positioning in the small-cap biotechnology sector, where large shareholders often utilize pre-funded warrants to manage ownership thresholds and regulatory reporting requirements.

Comparison to Industry Standards

• The use of a 9.99% ownership cap is a standard practice for institutional investors in small-cap biotech to avoid triggering 'control person' status under SEC regulations.
• The filing structure is consistent with standard Schedule 13G passive investment disclosures.

Stakeholder Impact

• Shareholders may view the presence of a 9.99% institutional holder as a sign of stability and long-term commitment to the company's capital structure.

Next Steps

• The reporting persons may file amendments to this Schedule 13G if there are material changes in their percentage of ownership.

Key Dates

Keywords

Eloxx Pharmaceuticals, Schedule 13G, Beneficial Ownership, Invus Group, Biotech Investment, Raymond Debbane